Stock Analysis on Net
Stock Analysis on Net

AbbVie Inc. (NYSE:ABBV)

Common-Size Balance Sheet: Liabilities and Stockholders’ Equity 

AbbVie Inc., common-size consolidated balance sheet: liabilities and stockholders’ equity

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Short-term borrowings 0.00 0.00 0.01 0.02 0.00
Current portion of long-term debt and finance lease obligations 5.34 2.98 8.52 5.62 4.21
Sales rebates 10.12 7.72 5.63 4.77 5.03
Dividends payable 2.07 1.93 1.74 1.55 1.99
Accounts payable 2.74 2.11 1.97 1.51 1.63
Current portion of contingent consideration liabilities 1.45 1.06 0.85 0.00 0.00
Salaries, wages and commissions 1.34 0.99 1.22 1.11 0.93
Royalty and license arrangements 0.27 0.30 0.45 0.32 0.36
Other 4.78 4.19 3.63 4.12 3.33
Accounts payable and accrued liabilities 22.75% 18.30% 15.49% 13.39% 13.28%
Current liabilities 28.09% 21.28% 24.02% 19.04% 17.49%
Long-term debt and finance lease obligations, excluding current portion 38.75 42.60 43.81 51.51 70.67
Deferred income taxes 1.45 1.58 2.05 2.42 1.27
Contingent consideration liabilities 13.32 10.75 9.31 8.16 8.08
Liabilities for unrecognized tax benefits 4.96 4.68 4.07 3.77 3.11
Income taxes payable 1.62 2.15 2.35 2.56 3.87
Pension and other post-employment benefits 1.14 1.18 2.15 2.27 3.31
Other 2.96 3.32 1.70 1.58 1.37
Other long-term liabilities 24.00% 22.08% 19.59% 18.34% 19.75%
Long-term liabilities 64.19% 66.27% 65.45% 72.27% 91.68%
Total liabilities 92.28% 87.55% 89.47% 91.30% 109.17%
Common stock, $0.01 par value 0.01 0.01 0.01 0.01 0.02
Common stock held in treasury, at cost -4.85 -3.31 -2.14 -1.50 -27.50
Additional paid-in-capital 14.98 13.86 12.49 11.55 17.05
Retained earnings (accumulated deficit) -0.74 3.45 2.13 0.70 5.29
Accumulated other comprehensive loss -1.71 -1.58 -1.98 -2.07 -4.04
Stockholders’ equity (deficit) 7.69% 12.43% 10.52% 8.68% -9.17%
Noncontrolling interest 0.03 0.02 0.02 0.01 0.00
Total equity (deficit) 7.72% 12.45% 10.53% 8.70% -9.17%
Total liabilities and equity (deficit) 100.00% 100.00% 100.00% 100.00% 100.00%

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

Balance sheet item Description The company
Current liabilities Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. AbbVie Inc. current liabilities as a percentage of total liabilities and equity (deficit) decreased from 2021 to 2022 but then increased from 2022 to 2023 exceeding 2021 level.
Long-term liabilities Amount of obligation due after one year or beyond the normal operating cycle, if longer. AbbVie Inc. long-term liabilities as a percentage of total liabilities and equity (deficit) increased from 2021 to 2022 but then decreased significantly from 2022 to 2023.
Total liabilities Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. AbbVie Inc. total liabilities as a percentage of total liabilities and equity (deficit) decreased from 2021 to 2022 but then increased from 2022 to 2023 exceeding 2021 level.
Stockholders’ equity (deficit) Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. AbbVie Inc. stockholders’ equity (deficit) as a percentage of total liabilities and equity (deficit) increased from 2021 to 2022 but then decreased significantly from 2022 to 2023.